Jessica Kaplan Altman MD

Hematologic Oncology

Professor in Medicine-Hematology/Oncology, Northwestern University Medical School

676 N Saint Clair StSte 850Chicago, IL 60611
Phone+1 312-695-4125
Fax+1 312-695-7814

Dr. Altman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Altman's full profile Already have an account?

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
University of ChicagoResidency, Internal Medicine, 2001 - 2004
University of Pittsburgh School of MedicineClass of 2001

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2024 - Present
IL State Medical License 2004 - 2029
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification PowerChart, Cerner Corporation, 2012-2017
CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2012-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
COMPLETED
PHASE2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
COMPLETED
PHASE2
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
COMPLETED

Publications & Presentations

PubMed

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.
Shiyu Xiao, Michihiro Kobayashi, Yunpeng Bai, Wenjie Cai, Sergio Barajas
Blood Advances. 2026-07-14
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.
Ivy E Abraham, Garth H Rauscher, Jerry Luo, Sarah Monick, Madelyn Burkart
Haematologica. 2026-07-01
QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed-ITD-negative acute myeloid leukemia.
Pau Montesinos, Jessica K Altman, Lars Bullinger, June-Won Cheong, Amir T Fathi
Future Oncology. 2026-07-01

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Lectures

Targeting Treatment According to Molecular Assessment of Acute Myeloid Leukemia
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
MDS + AML MATTER: A Multidisciplinary Approach to Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection
60th American Society of Hematology Annual Meeting - 12/1/2018
Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

ALL: Which Life-Saving Tx Is Best?April 12th, 2024
Improving Treatment for Hairy Cell LeukemiaJanuary 11th, 2023
Study Shows Structural Racism Can Result in Poorer Leukemia OutcomesMarch 7th, 2022